Madrigal Pharmaceuticals (MDGL) Enterprise Value (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Enterprise Value of -$838.8 million for Q2 2026, down 5.24% year-over-year from -$885.1 million in Q2 2025, and down 3.2% quarter-over-quarter from -$812.8 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Enterprise Value (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Enterprise Value for 17 consecutive years, with -$838.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 5.24% year-over-year to -$838.8 million; the TTM figure through Jun 2026 stood at -$838.8 million (down 5.24% YoY), while the FY2025 annual figure was -$983.6 million, down 6.19% from the prior year.
- Enterprise Value slipped to -$838.8 million in Q2 2026 per MDGL's latest filing, from -$812.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$153.2 million in Q3 2022 and bottomed at -$1.1 billion in Q3 2025.
- Historically, Enterprise Value has averaged -$659.2 million across 5 years, with a median of -$804.9 million in 2025.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 48.79% — and 2024, when it slumped 329.79%.
- Madrigal Pharmaceuticals' Enterprise Value stood at -$358.8 million in 2022, then sank by 76.75% to -$634.1 million in 2023, then slumped by 46.07% to -$926.3 million in 2024, then declined by 6.19% to -$983.6 million in 2025, then increased by 14.72% to -$838.8 million in 2026.
- Business Quant data shows MDGL's Enterprise Value at -$838.8 million in Q2 2026, -$812.8 million in Q1 2026, and -$983.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -838.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -838.75 Mn |
| Mar 31, 2026 | -232.23 Mn |
| Dec 31, 2025 | -983.56 Mn |
| Sep 30, 2025 | -1.11 Bn |
| Jun 30, 2025 | -797.02 Mn |
| Mar 31, 2025 | -843.07 Mn |
| Dec 31, 2024 | -105.02 Mn |
| Sep 30, 2024 | -998.63 Mn |
| Jun 30, 2024 | -1.06 Bn |
| Mar 31, 2024 | -1.06 Bn |
| Dec 31, 2023 | -634.13 Mn |
| Sep 30, 2023 | -232.35 Mn |
| Jun 30, 2023 | -298.42 Mn |
| Mar 31, 2023 | -329.48 Mn |
| Dec 31, 2022 | -358.77 Mn |
| Sep 30, 2022 | -153.19 Mn |
| Jun 30, 2022 | -211.77 Mn |
| Mar 31, 2022 | -219.95 Mn |
| Dec 31, 2021 | -270.35 Mn |
| Sep 30, 2021 | -299.14 Mn |